STOCK TITAN
  1. Home
  2. News
  3. TNDM

Tandem Diabetes Care, Inc. - TNDM STOCK NEWS

Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.

Tandem Diabetes Care, Inc. (symbol: TNDM) is a leading medical device company committed to enhancing the lives of individuals with diabetes through continuous innovation and a customer-first approach. Based in San Diego, California, Tandem focuses on the design, development, and commercialization of advanced insulin pump technologies.

The company's flagship products include the t:slim X2™ insulin pump, noted for its unique ability to receive remote feature updates via a personal computer, and the t:flex® insulin pump, which is tailored for patients with higher insulin requirements. These devices are designed to offer users greater flexibility, control, and ease of use, significantly improving diabetes management.

In addition to these main products, Tandem has introduced the Mobi pump, a smaller, more discreet device, and is actively working on developing a tubeless pump to further enhance user convenience and experience. The company's product portfolio generates substantial revenue from both the insulin pumps themselves and the accompanying disposable infusion sets, which need regular replacement every 2 to 3 days.

Approximately 75% of Tandem's total revenue comes from the U.S. market, with the remaining sales derived from other developed countries. The company's strong focus on innovation and user experience has cemented its position as a trusted name in diabetes care.

For the latest updates and relevant information about Tandem Diabetes Care, Inc., including recent achievements, ongoing projects, financial performance, and strategic partnerships, stay tuned to our news section.

Note: This description is for informational purposes only and is not intended for product support or medical advice. In case of a medical emergency, please dial 911. For immediate assistance with Tandem products, contact the 24-hour customer support team at 877-801-6901, pressing 1 twice.

News

Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes

Rhea-AI Summary
Tandem Diabetes Care, Inc. plans to offer $250.0 million of Convertible Senior Notes due 2029 in a private placement. The notes will be general unsecured obligations and will accrue interest semiannually. Tandem intends to use the net proceeds for capped call transactions, repurchasing existing notes, and buying back common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.96%
Tags
none
-
News

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance

Rhea-AI Summary
Tandem Diabetes Care, Inc. (TNDM) reports strong financial results for Q4 and FY 2023, with an increase in installed base, new product launches, and financial guidance for 2024. The company achieved positive momentum across key areas, including revenue growth, product launches, and operational improvement. The financial results show growth in sales, both in the US and internationally, with a focus on recurring revenue streams. Tandem aims to improve the lives of people with diabetes worldwide through its innovative products and platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.86%
Tags
earnings
-
News

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) launches Tandem Mobi, the world's smallest durable automated insulin delivery system in the US. The Control-IQ technology predicts and prevents high and low blood sugar, improving time in range. The system is impressively small, wearable, and compatible with various infusion sets and sensors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
News

Tandem Diabetes Care Announces Upcoming Conference Presentations

Rhea-AI Summary
Tandem Diabetes Care, Inc. (TNDM) will present a company update at several investor conferences in February and March 2024. The presentations will be webcast live and accessible on the company's Investor Center website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
-
News

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024

Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to release its Q4 and full year 2023 results on February 21, 2024, followed by a conference call and webcast to discuss the financial and operating results. The webcast will be available on Tandem Diabetes Care’s Investor Center website, and an archive will be accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
earnings
-
News

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Rhea-AI Summary
Abbott (ABT) and Tandem Diabetes Care (TNDM) have announced the integration of the FreeStyle Libre 2 Plus sensor with the t:slim X2 insulin pump in the U.S. This marks the first time that Tandem's Control-IQ technology is compatible with the 15-day continuous glucose monitoring (CGM) sensor, providing a hybrid closed-loop system for users in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
News

ACRO Announces 2024 Officers and New Members

Rhea-AI Summary
ACRO (Association of Clinical Research Organizations) announced the election of Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024. Lisa Moneymaker, Chief Technology Officer & Chief Product Officer at Saama, was elected Vice Chair. Mike Crowley, Chief Administrative Officer & General Counsel at Parexel, was elected Secretary, and Ari Feldman, Senior Vice President, Global Compliance and Strategy at Medidata Solutions, was re-elected Treasurer. ACRO also welcomed Advarra and YPrime as its newest members, reflecting the association's continued evolution in representing CROs and clinical technology companies that support drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
none
-
News

Tandem Diabetes Care Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers. This platform consolidates various features into one central location, providing comprehensive data reporting and easy access to therapy data, supply reordering, and pump software updates. The platform has received positive feedback from early adopters in the United States and is expected to be available internationally by 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
none
-
News

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.

Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) launches updated t:slim X2™ insulin pump software with Dexcom G7 Continuous Glucose Monitoring (CGM) integration in the United States. This marks the first automated insulin delivery system in the world to feature Dexcom’s most advanced CGM technology. The integration allows t:slim X2 insulin pump users to spend more time in closed loop with little to no wait time between Dexcom G7 CGM sensor sessions. The Dexcom G7 is 60 percent smaller than its predecessor, offers improved accuracy, a 30-minute sensor warmup time, and a 12-hour grace period to replace finished sensors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
none
News

Tandem Diabetes Care Announces Upcoming Conference Presentations

Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present a company update at several investor conferences. The presentations will be webcast live and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
conferences

FAQ

What is the current stock price of Tandem Diabetes Care (TNDM)?

The current stock price of Tandem Diabetes Care (TNDM) is $30.81 as of November 22, 2024.

What is the market cap of Tandem Diabetes Care (TNDM)?

The market cap of Tandem Diabetes Care (TNDM) is approximately 2.0B.

What is Tandem Diabetes Care, Inc. known for?

Tandem Diabetes Care, Inc. is known for designing, manufacturing, and marketing advanced insulin pumps for diabetes management, including the t:slim X2™ and t:flex® pumps.

Where is Tandem Diabetes Care, Inc. located?

Tandem Diabetes Care, Inc. is headquartered in San Diego, California.

What are the main products of Tandem Diabetes Care, Inc.?

The main products of Tandem Diabetes Care, Inc. include the t:slim X2™ insulin pump and the t:flex® insulin pump, as well as the newly launched Mobi pump.

How do the t:slim X2™ insulin pump updates work?

The t:slim X2™ insulin pump can receive remote feature updates using a personal computer, allowing users to access the latest technology without needing to replace the pump.

What percentage of Tandem Diabetes Care's revenue comes from the U.S.?

Approximately 75% of Tandem Diabetes Care's total revenue is derived from the U.S. market.

Does Tandem Diabetes Care offer customer support?

Yes, Tandem Diabetes Care offers 24-hour customer support. For immediate assistance with their products, customers can call 877-801-6901 and press 1 twice.

What recent products has Tandem Diabetes Care introduced?

Tandem Diabetes Care recently launched the smaller Mobi pump and is currently working on developing a tubeless pump.

What materials are required to replace in Tandem's insulin pumps?

Disposable infusion sets, which need to be changed every 2 to 3 days, are required replacements for Tandem's insulin pumps.

What is the unique feature of the t:flex® insulin pump?

The t:flex® insulin pump is designed specifically for people with greater insulin requirements, offering more flexibility in diabetes management.

How does Tandem Diabetes Care innovate in diabetes care?

Tandem Diabetes Care focuses on a user-centric approach to design and development, ensuring their products are both innovative and user-friendly, enhancing the overall diabetes management experience.

Stock TNDM logo
Tandem Diabetes Care, Inc.

Nasdaq:TNDM

TNDM Rankings

#1992 Ranked by Market Cap
N/A Ranked by Dividends

TNDM Stock Data

2.02B
65.14M
0.75%
114.24%
12.78%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
San Diego